Clinuvel Pharmaceuticals Ltd (ASX: CUV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clinuvel Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$455.87 million
P/E Ratio
13.64
Dividend Yield
0.57%
Shares Outstanding
50.43 million
Earnings per share
0.644
Dividend per share
0.05
Year To Date Return
-27.37%
Earnings Yield
7.33%
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clinuvel Pharmaceuticals Ltd (ASX: CUV)
Latest News
Share Market News
Which ASX shares are ending the week as the biggest movers today?
Share Market News
ASX 200 midday update: Wesfarmers' $2.3bn capital return, Appen & Pilbara Minerals fall
Earnings Results
Clinuvel (ASX:CUV) share price gains 5% on FY21 profit boost
Share Market News
ASX 200 Weekly Wrap: COVID wobbles ASX as shares retreat
Share Fallers
These were the worst performing ASX 200 shares last week
Share Fallers
Why Australian Ethical, Clinuvel, Liontown Resources, & Tabcorp shares are dropping
Share Market News
ASX 200 Weekly Wrap: ASX finishes FY21 on a high
Share Gainers
These were the best performing ASX 200 shares last week
Share Market News
Clinuvel (ASX:CUV) share price lower despite positive update
Share Gainers
Here's why the Clinuvel (ASX:CUV) share price is pushing higher
Share Market News
Clinuvel (ASX:CUV) share price drops on strategic update
Share Market News
Clinuvel (ASX:CUV) share price falls despite positive update
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 05 Sep 2024 | $0.0500 | 100.00% | Final | 20 Sep 2024 |
| 05 Sep 2023 | $0.0500 | 100.00% | Final | 20 Sep 2023 |
| 06 Sep 2022 | $0.0400 | 100.00% | Final | 21 Sep 2022 |
| 02 Sep 2021 | $0.0250 | 0.00% | Final | 17 Sep 2021 |
| 03 Sep 2020 | $0.0250 | 0.00% | Final | 18 Sep 2020 |
| 04 Sep 2019 | $0.0250 | 0.00% | Final | 19 Sep 2019 |
| 21 Sep 2018 | $0.0200 | 0.00% | Final | 08 Oct 2018 |
CUV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clinuvel Pharmaceuticals Ltd
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
CUV Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 23 Apr 2026 | $8.81 | $0.02 | 0.23% | 174,213 | $8.70 | $9.02 | $8.57 |
| 22 Apr 2026 | $8.79 | $-0.26 | -2.87% | 156,013 | $9.16 | $9.16 | $8.71 |
| 21 Apr 2026 | $9.05 | $-0.11 | -1.20% | 175,837 | $9.10 | $9.15 | $8.90 |
| 20 Apr 2026 | $9.16 | $0.01 | 0.11% | 121,129 | $9.20 | $9.29 | $9.02 |
| 17 Apr 2026 | $9.15 | $-0.08 | -0.87% | 143,668 | $9.25 | $9.30 | $9.06 |
| 16 Apr 2026 | $9.23 | $0.09 | 0.98% | 91,112 | $9.18 | $9.37 | $9.16 |
| 15 Apr 2026 | $9.14 | $0.01 | 0.11% | 79,640 | $9.15 | $9.31 | $9.13 |
| 14 Apr 2026 | $9.13 | $0.04 | 0.44% | 65,609 | $9.10 | $9.32 | $9.07 |
| 13 Apr 2026 | $9.09 | $0.00 | 0.00% | 92,160 | $9.03 | $9.17 | $8.91 |
| 10 Apr 2026 | $9.09 | $-0.02 | -0.22% | 118,964 | $9.13 | $9.16 | $9.00 |
| 09 Apr 2026 | $9.11 | $-0.21 | -2.25% | 66,152 | $9.30 | $9.38 | $9.01 |
| 08 Apr 2026 | $9.32 | $0.31 | 3.44% | 127,159 | $9.04 | $9.36 | $8.96 |
| 07 Apr 2026 | $9.01 | $-0.01 | -0.11% | 126,382 | $9.05 | $9.48 | $8.97 |
| 02 Apr 2026 | $9.02 | $-0.72 | -7.39% | 259,756 | $9.66 | $9.73 | $9.00 |
| 01 Apr 2026 | $9.74 | $-0.15 | -1.52% | 107,638 | $9.99 | $9.99 | $9.60 |
| 31 Mar 2026 | $9.89 | $0.11 | 1.12% | 78,252 | $9.70 | $9.94 | $9.60 |
| 30 Mar 2026 | $9.78 | $-0.12 | -1.21% | 149,456 | $9.95 | $9.98 | $9.63 |
| 27 Mar 2026 | $9.90 | $0.12 | 1.23% | 47,881 | $9.87 | $10.10 | $9.58 |
| 26 Mar 2026 | $9.78 | $-0.07 | -0.71% | 50,454 | $9.96 | $9.96 | $9.63 |
| 25 Mar 2026 | $9.85 | $0.22 | 2.28% | 52,078 | $9.90 | $9.93 | $9.60 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mrs Susan (Sue) Smith | Non-Executive Director | Sep 2019 |
Mrs Smith manages an established consultancy business, providing advisory services to a range of healthcare organizations, investors and boards of directors. She has led a career, serving for 14 years as Chief Executive Officer of The Princess Grace Hospital, London, and 11 years as the Chief Executive Officer of The Portland Hospital for Women and Children, London. Her most recent role was as the Chief Executive Officer of the Independent Doctors Federation, a membership organisation representing practising physicians within the UK independent healthcare sector. She is also the Director of HCA Hope Fund UK. She is a member of the Commercial Committee.
|
| Dr Philippe J Wolgen | Chief Executive OfficerManaging Director | Dec 2005 |
Dr Wolgen's leadership led to a long-term strategy for CLINUVEL. The product SCENESSE was reformulated, its medical application identified, European marketing authorization was obtained in 2014, and systems were established to self-distribute the prescriptive product in the European Economic Area from June 2016. He oversaw the submission of the scientific dossier to the US Food & Drug Administration (FDA) under a New Drug Application, which was approved in October 2019.
|
| Dr Karen Agersborg | Non-Executive Director | Jan 2018 |
Dr Agersborg is a clinical endocrinologist with diverse and extensive practice experience in Pennsylvania and New Jersey, U.S.A. She is Board Certified in both Internal Medicine and Endocrinology, Diabetes & Metabolism and holds specific expertise on the class of melanocortins. Her career has included inpatient, outpatient, and hospitalist positions across several prominent medical institutions. She is an Associate Professor of Medicine, teaching medical students and residents in endocrinology. She had a career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories).
|
| Professor Jeffrey Rosenfeld | Non-Executive ChairmanNon-Executive Director | Nov 2019 |
Prof Rosenfeld is a neurosurgeon with experience in senior healthcare and medical research executive roles and a distinguished and decorated career in the Australian Army. He is a retired Major General and a former Surgeon General, Australian Defence Force Reserves. He has served on eight deployments to Rwanda, Iraq, Solomon Islands, Bougainville and East Timor. He was the Founding Director of Monash University Institute of Medical Engineering (MIME)-Melbourne. He is a Member of the Risk Committee.
|
| Mr Matthew William Pringle | Non-Executive Director | Sep 2024 |
Mr Pringle has three decades of expertise in corporate finance, audit and assurance, governance, and strategic advisory. He served as a Partner at Pitcher Partners for more than 25 years, where he held key leadership roles including Head of Corporate Finance Practice, Senior Audit Partner, and Lead of the Corporate Governance and Board Advisory Practice. He currently serves as a non-executive director on several unlisted public, private and for purpose Boards, contributing his deep financial and governance acumen to both commercial and community-focused organizations. He is Chair of the Risk Committee and Member of the Commercial Committee.
|
| Dr Pearl E Grimes | Non-Executive Director | Sep 2024 |
Dr Grimes is the Founder and Director of the Vitiligo and Pigmentation Institute of Southern California where she treats patients from all over the world. She is also the director of the Grimes Institute for Medical and Aesthetic Dermatology, where she treats a wide range of dermatologic health and aesthetic concerns in patients of all ethnicities and skin types. She also serves as a Clinical Professor of Dermatology at the David Geffen School of Medicine at UCLA and Chief Dermatologist for Versicolor Technologies. She is Member of the Commercial Committee.
|
| Mr Guy van Dievoet | Non-Executive Director | Sep 2024 |
Mr Dievoet has experience in investment banking, specialising in M&A. In this capacity he has worked for leading financial institutions, including the Merchant bank of IndoSuez in Belgium, ABN-AMRO, Bank BNP Group, and as executive-director for MeesPierson. He is Member of the Risk Committee and Chair of the Commercial Committee.
|
| Ms Claire Newstead-Sinclair | Company Secretary | Aug 2024 |
-
|
| Mr P Vaughan | Chief Financial Officer |
-
|
|
| Mr L Hay | Chief Operating Officer |
-
|
|
| Dr D Wright | Chief Scientific Officer |
-
|
|
| Claire Newstead-Sinclair | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 9,683,928 | 19.32% |
| BNP Paribas Nominees Pty Ltd (Clearstream) | 5,807,164 | 11.59% |
| Citicorp Nominees Pty Limited | 4,324,933 | 8.63% |
| BNP Paribas Nominees Pty Ltd | 3,642,332 | 7.27% |
| Dr Philippe Jacques Wolgen | 3,425,222 | 6.83% |
| J P Morgan Nominees Australia Pty Limited | 3,231,434 | 6.45% |
| Ender 1 LLC | 2,590,824 | 5.17% |
| BNP Paribas Nominees Pty Ltd (IB AU Norns Retail Client) | 2,389,515 | 4.77% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 1,179,682 | 2.35% |
| Emilino Group Pty Ltd (Emilino Super Fund A/C) | 600,000 | 1.20% |
| National Nominees Limited | 459,695 | 0.92% |
| BNP Paribas Nominees Pty Ltd (Agency Lending A/C) | 308,064 | 0.61% |
| Dr Mark Edwin Badcock | 270,255 | 0.54% |
| Mr Darren Michael Kearny | 242,890 | 0.48% |
| Mr David William Trevorrow | 229,600 | 0.46% |
| Dr Dennis Wright | 192,312 | 0.38% |
| Mr David John Lewis | 185,000 | 0.37% |
| Mr Trent Sheldon Redding | 174,800 | 0.35% |
| Mr Simon John Bown | 146,000 | 0.29% |
| Rusty Hammer Pty Ltd (Archipelago Holdings Super Fund A/C) | 144,175 | 0.29% |